Biocon An Indian biotechnology company founded in 1978 by Kiran Mazumdar-Shaw, Biocon has world-class research outsourcing capabilities, US FDA-compliant bio-manufacturing facilities and a self-financed R&D pipeline . It was included in ‘The best under a billion’ listing by Forbes in 2009. and was adjudged the best listed company in the Asia-Pacific region by BioSingapore based on its market capital, sound business model and excellent management team in the same year.[ref 3] Employing 4,500 people, it is regarded as the 7th largest employer among the top 100 global biotechnology companies.
Located in Bangalore, India, Biocon has two subsidiaries, Syngene, a custom research organization, and Clinigene, a clinical research organization. Biocon’s presence straddles four main therapeutic areas – Diabetology, Cardiology, Nephrology and Oncology – even as it plans to introduce two new divisions, Comprehensive Care, and Immunotherapy, this year.
Biocon’s cardiology, nephrology, diabetology and oncology products including BESTOR®, BASALOGTM, BioMAb EGFR®, STATIX®, NUFIL safeTM, INSUGEN®, TACROGRAFTM, ERYPRO safeTM, and MYOKINASETM are considerably less expensive than other leading brands.[ref 1] Two of its novel programs on the verge of proof-of-concept stage are IN-105, which is the only oral insulin in the world to be in long duration clinical trials, and the T1h, a novel humanized monoclonal antibody (MAb), the only first-in-class novel MAb being tested in India for rheumatoid arthritis and psoriasis.
Between 2005 and 2010, Biocon entered into more than 2,200 high-value R&D licensing and other deals within the pharmaceuticals and bio-pharmaceutical space.[ref 1] It has also expanded its global footprint to emerging and developed markets through acquisitions, partnerships and in-licensing. Biocon’s Corporate Social Responsibility wing, the Biocon Foundation, is involved in numerous health and education outreach programs targeting the underprivileged sections of India.
In 2009-10, Biocon’s net income increased 44% to Rs. 24,048 million, crossing the half-billion-dollar mark and profits grew 215% to Rs. 2,933 million. The pharmaceutical business exceeded Rs. 200,871 million in revenue and the net R&D expenditure increased to Rs. 917 million, growing 42% over 2008 and up 282% over 2005, while its research services business crossed Rs. 2,807 million.
Biocon, Syngene and Clinigene together employ approximately 4,500 personnel including biologists, chemists, medical practitioners, pharmacologists, engineers, finance/legal/marketing analysts, HR generalists and general administrators. Around 6% of its employees have PhD degrees, 45% have a master’s degree, and 33% are graduates. Biocon also collaborates with educational institutes to make courses more industry oriented..
thank you all
